Contraceptive access gaps driven by federal rollbacks, provider shortages, and stalled state legislation could be narrowed by letting trained pharmacists prescribe birth control independently.
|Podcasts|February 18, 2022
Pharmacist Moms: Coffee With Suzy - Episode 5
In the fifth episode of Coffee With Suzy, Suzanne Soliman, PharmD, BCMAS, sat down with Joanna Lewis, PharmD, MBA and Christina Madison, PharmD, FCCP, AAHIVP.
Advertisement
In the fifth episode of Coffee With Suzy, Suzanne Soliman, PharmD, BCMAS, sat down with Joanna Lewis, PharmD, MBA and Christina Madison, PharmD, FCCP, AAHIVP to discuss the ongoing challenges of burnout in the pharmacy and insights on mental health.
Advertisement
Related to this article
The FDA has approved rebisufligene etisparvovec-hopf (Fayuvi), the first treatment designed to alter the course of mucopolysaccharidosis type IIIA.
This update came with no changes to the safety sections of labeling, with no new signals identified with longer follow-up.
Professional membership and experienced mentor leadership offer new pharmacy technicians a dual advantage, serving as a comprehensive training accelerator.
A biologic stewardship framework can enhance consistency, safety, and sustainability of biologic use in health systems.
The update shortens required observation to 6 to 8 hours from 22 to 24, easing tarlatamab administration in community settings for ES-SCLC.
Thomas Hope, MD, explains why radioligand therapies should be evaluated according to whether their clinical benefits outweigh their risks within the context of patients’ available cancer treatment options.
The approval is supported by data from the phase 3 FINE-ONE clinical trial.
Advertisement
Advertisement
Trending on Pharmacy Times
1
Adult Pneumococcal Immunizations: A Practical Guide for Pharmacists
2
How Pharmacists Overcome PCSK9 Inhibitor Access Barriers
3
FDA Approves Rebisufligene Etisparvovec as First Gene Therapy for Children With Sanfilippo Syndrome Type A
4
Beyond Cost Avoidance: Advancing Unit-Level Pharmaceutical Economics in Health Systems
5